Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: A prospective cohort study

Drug Safety

Volumn 33, Issue 7, 2010, Pages 605-613

  Harrison Woolrych, Mira ^a   Ashton, Janelle ^a   Herbison, Peter ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse reactions; Cardiovascular disorders; Drug induced; Obesity therapies; Postmarketing surveillance; Sibutramine

Indexed keywords

SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIZZINESS; DRUG EXPOSURE; DRUG FATALITY; DYSPNEA; FAINTNESS; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; METASTASIS; MORTALITY; NEW ZEALAND; OBESITY; OBSERVATIONAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREAS CARCINOMA; PERIPHERAL EDEMA; POPULATION; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; SHOCK; SIDE EFFECT; STROKE; T WAVE INVERSION; TACHYCARDIA; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; MIDDLE AGED; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYCLOBUTANES; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; NEW ZEALAND; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 77953591831     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11532440-000000000-00000     Document Type: Article

References (19)

1. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorizations for sibutramine. 21 January 2010 [press release; online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ referral/sibutramine/3940810en.pdf [Accessed 2010 May 11]
2. US Food and Drug Administration. Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm198221.htm [Accessed 2010 May 19]
3. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardio-vascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915-2923
4. Thirty-four deaths in sibutramine patients. Scrip 2002; 2730: 23
5. Advisory. Health Canada reports back to public on safety profile of Meridia (sibutramine). Ottawa (ON): Health Canada, 2003 Feb 28 [online]. Available from URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2003/ 2003- 07-eng.php [Accessed 2010 May 19]
6. Harrison-Woolrych ML, Coulter DM. PEM in New Zealand. In: Mann R, Andrews EB, editors. Pharmacovigilance. 2nd edition. Chichester: John Wiley and Sons, 2007: 317-332
7. Harrison-Woolrych ML, Clark DWJ, Hill GR, et al. QT interval prolongation associated with sibutramine. Br J Clin Pharmacol 2006; 61 (4): 464-469
8. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340: c824
9. Kunac DL, Harrison-Woolrych ML, Tatley MV. Pharma-covigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. NZ Med J 2008; 121; 1281: 76-89 [online]. Available from URL: http://www.nzma.org.nz/journal/121-1283/3286 [Accessed 2010 May 11]
10. NZ Ministry of Health. Data and statistics: mortality col-lection (MORT) [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/ dataandstatistics-collections-mortality [Accessed 2010 May 11]
11. Hill G, Harrison-Woolrych ML, Ashton J. Sibutramine utilisation in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. Phar-macoepidemiol Drug Saf 2007; 16: 1217-1226
12. Ajani UA, Lotufo PA, Gaziano JM. Body mass index and mortality among US male physicians. Ann Epidemiol 2004; 14: 731-739
13. James WP, Astrup A, Finer N, et al. Effect of sibutramineon weight maintenance after weight loss: a randomised trial. STORM Study Group. Lancet 2000; 356: 2119-2125
14. Abbott Laboratories (NZ) Ltd. New Zealand datasheet for Reductil [online]. Available from URL: http://www.med-safe.govt.nz/profs/Datasheet/r/ Reductilcap.pdf [Accessed 2010 May 19]
15. Russell DG, Wilson NC, Parnell WR, et al. NZ food: NZ people. Key results of the 1997 National Nutrition Survey. Wellington: Ministry of Health, 1999 [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/pagesmh/852 [Accessed 2010 May 11]
16. Calle EE, Thun MJ, Petrelli JM, et al. Body mass index and mortality in a prospective cohort study of US adults. N Engl J Med 1999; 341 (15): 1097-1105
17. Ernest D, Gershenzon A, Corallo CE, et al. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008; 42: 1514-1517
18. Eroglu E, Gemici G, Bayrak F, et al. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009; 137: e43-5
19. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007; 28: 2830-2831